India's Jubilant Pharmova rises after unit gets US FDA approval
** Shares of Jubilant Pharmova JUBA.NS up as much as 6.5%
to 438.90 rupees
** The pharma co said its unit Jubilant Draximage got U.S.
FDA approval for its abbreviated new drug application for
preparation kit of a drug used for treating breast and skin
cancer
** Over 673,000 shares change hands, 1.7x the 30-day moving
average
** Including session's move, stock up ~15% YTD
(Reporting by Kashish Tandon in Bengaluru)
((kashish.tandon@thomsonreuters.com))
Recent news on Jubilant Pharmova
See all newsBrief: Jubilant Pharmova Sept-Quarter Consol Net Profit 312 Million Rupees
Brief: Jubilant Pharmova Says Jubilant Therapeutics Announces Oral Presentation Of Preliminary Phase 1 Clinical Data For JBI-802
India New Issue-Jubilant Pharmova to issue 3-year bonds, bankers say
India's Jubilant Pharmova eyes $150 mln through rupee debt sale, bankers say
Brief: Jubilant Pharmova To Consider Raising Of Funds Through Issuance Of Non- Convertible Debentures